trastuzumab

This page shows the latest trastuzumab news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.

Latest news

Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more

The Institute had already rejected it in this setting in June, but looked again to see if the arrival biosimilars of Herceptin (trastuzumab) – which is administered with Perjeta – would help improve ... NICE already recommends Perjeta with
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar

Pfizer has gained European approval for its Herceptin (trastuzumab) biosimilar product, Trazimera.
Amgen’s R&D chief Sean Harper retires to seek biotech post

of Amgen’s first biosimilar Kanjinti, a version of Roche’s breast cancer blockbuster Herceptin (trastuzumab).
Bluebird and Celgene BCMA CAR-T kicks off ASCO

to license it to Seattle Genetics last year - while other breast cancer ADCs on the agenda at ASCO include Daiichi is developing trastuzumab deruxtecan and Takeda/Mersana’s XMT-1522.
Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more

Biosimilars: Herzuma launched in Europe, FDA rejects Sandoz rituximab. Mundipharm has launched Herzuma, its biosimilar version of Roche’s Herceptin trastuzumab in Europe.

More from news
Approximately 15 fully matching, plus 155 partially matching documents found.

Latest Intelligence

2016: The year when deal-makers took stock?

Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab).
Deal Watch October 2016

Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.
Current development and marketing of biosimilar monoclonal antibodies in Latin America

7). OliMed. Trastuzumab. Celltrion. South Korea. CT-P06. Clinical. BC: Ph III completed in Dec 2011.
An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S Korea.
Tough times for pharma in Portugal

In other cases there is a significant decrease in spending on drugs such as Roche's Herceptin (trastuzumab) for breast cancer, which the company explains through price reductions.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

AVEO's financial head joins ImmunoGen

cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche. “

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Sudler London - Account Director: Competitive

Graduate Scientific Editor: DOE

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Director or Senior Account Director: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Systematic Review Lead- London: Negotiable

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Manager- 4 days per week or full-time: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Associate Scientific Director: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Market Access Consultant - Greater Manchester: Negotiable

Healthcare PR Senior Account Manager: Salary TBC

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior Medical Writer: Salary is DOE

Healthcare PR Director: £100, 000 – £120, 000 benefits

Subscribe to our email news alerts

PMHub

Add my company

Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....